Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: A double-blind, randomized, placebo-controlled study

American Journal of Psychiatry

Volumn 169, Issue 8, 2012, Pages 813-821

  Wu, Ren Rong ^a,b,c,d,e,f   Jin, Hua ^a,b,c,d,e,f   Gao, Keming ^a,b,c,d,e,f   Twamley, Elizabeth W ^a,b,c,d,e,f   Ou, Jian Jun ^a,b,c,d,e,f   Shao, Ping ^a,b,c,d,e,f   Wang, Juan ^a,b,c,d,e,f   Guo, Xiao Feng ^a,b,c,d,e,f   Davis, John M ^a,b,c,d,e,f   Chan, Philip K ^a,b,c,d,e,f   Zhao, Jing Ping ^a,b,c,d,e,f  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f HANGZHOU SEVENTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; LUTEINIZING HORMONE; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROLACTIN; RISPERIDONE; SULPIRIDE; TESTOSTERONE;

ADULT; AGITATION; AMENORRHEA; ARTICLE; BODY MASS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPOGLYCEMIA; INSOMNIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MENSTRUATION; NAUSEA; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84864805808     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.11091432     Document Type: Article

References (37)

1. Wieck A, Haddad PM: Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity, and consequences. Br J Psychiatry 2003; 182:199-204 (Pubitemid 36286731)
2. Alvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, Hetrick S, Rodríguez-Sánchez JM, Pérez-Iglesias R, Vázquez-Barquero JL: Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008; 22:547-562
3. Teede H, Deeks A, Moran L: Polycystic ovary syndrome: a complex condition with psychological, reproductive, and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8:41
4. Colton CW, Manderscheid RW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006; 3:A42
5. Chiang YL, Klainin-Yobas P, Ignacio J, Chng CM: The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders. J Clin Nurs 2011; 20:2172-2182
6. Kane JM: Addressing side effects from antipsychotic treatment in schizophrenia. J Clin Psychiatry 2011; 72:e07
7. Pringsheim T, Lam D, Ching H, Patten S: Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf 2011; 34:651-668
8. Fric M, Laux G: [Prolactin levels and symptoms of hyperprolactinemia in patients treated with amisulpride, risperidone, olanzapine, and quetiapine.] Psychiatr Prax 2003; 30(suppl 2):97-101 (German)
9. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696 (Pubitemid 29517559)
10. Wu RR, Zhao JP, Liu ZN, Zhai JG, Gao XF, Guo WB, Tang JS: Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006; 186:572-578
11. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL: H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28:519-526
12. Matsui-Sakata A, Ohtani H, Sawada Y: Receptor occupancy-based analysis of the contribution of various receptors to antipsychotic-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005; 20:368-378
13. Bailey CJ, Turner RC: Metformin. N Engl J Med 1996; 334:574-579 (Pubitemid 126537875)
14. Uehara MH, Kohlmann NE, Zanella MT, Ferreira SR: Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab 2001; 3:319-325 (Pubitemid 33072212)
15. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH: Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008; 165:352-358
16. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, He YQ, Liu YJ, Chen JD, Li LH: Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008; 299:185-193
17. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure while facilitating normal menses and pregnancy. Metabolism 1994; 43:647-654 (Pubitemid 24145474)
18. Billa E, Kapolla N, Nicopoulou SC, Koukkou E, Venaki E, Milingos S, Antsaklis A, Adamopoulos DA: Metformin administration was associated with a modification of LH, prolactin, and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol Endocrinol 2009; 25:427-434
19. Palomba S, Falbo A, Zullo F, Orio F Jr: Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009; 30:1-50
20. Wang D, Chen JJ, Yu L: Clinical study of metformin in young obese women with amenorrhea. Journal of Jiangsu University 2007; 17:498-502
21. Qu S, Hui L, Gao CR: Therapeutic effect of metformin in obese women with amenorrhea. Chinese Journal of Endocrinology and Metabolism 2003; 19:207-208
22. Lee MS, Song HC, An H, Yang J, Ko YH, Jung IK, Joe SH: Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci 2010; 64:19-27
23. Ortega-González C, Cardoza L, Coutiño B, Hidalgo R, Arteaga-Troncoso G, Parra A: Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol 2005; 184:233-239
24. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version. Washington, DC, American Psychiatric Press, 1997
25. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 341-350
26. Haffner SM, Miettinen H, Stern MP: The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20:1087-1092 (Pubitemid 27274268)
27. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA: A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163:2072-2079 (Pubitemid 46114226)
28. Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, Schildkraut JJ, Green AI: Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 2002; 111:11-20 (Pubitemid 34879071)
29. Prentice DS, Deakin FW: Role of neuroleptic drugs and organic mechanisms in the aetiology of menstrual irregularities in schizophrenic women. Schizophrenia Res 1992; 6:114
30. Savage DB, Semple RK, Chatterjee VK, Wales JK, Ross RJ, O'Rahilly S: A clinical approach to severe insulin resistance. Endocr Dev 2007; 11:122-132
31. Fitzgerald PB, Scaffidi A, Morris MJ, de Castella AR, Kulkarni J: The relationship of changes in leptin, neuropeptide Y, and reproductive hormones to antipsychotic induced weight gain. Hum Psychopharmacol 2003; 18:551-557 (Pubitemid 37279237)
32. Molitch ME: Prolactin, in The Pituitary. Edited by Melmed S. Cambridge, UK, Blackwell Scientific Science, 1995, pp 136-186
33. Weinhaus AJ, Stout LE, Bhagroo NV, Brelje TC, Sorenson RL: Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. J Endocrinol 2007; 193:367-381 (Pubitemid 47028688)
34. Melkersson K, Berinder K, Hulting AL: Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity, and lipid profile in patients with schizophrenia or related psychoses. Neuro Endocrinol Lett 2011; 32:428-436
35. Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM: Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 2007; 23:146-152 (Pubitemid 46570211)
36. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003; 163:2594-2602 (Pubitemid 37464417)
37. Liu KW, Dai LK, Jean W: Metformin-related vitamin B12 deficiency. Age Ageing 2006; 35:200-201